[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transfusion-dependent-thalassemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transfusion-dependent-thalassemia":78},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100641748","the-effect-of-motivational-interviewing-on-treatment-adherence-and-self-efficacy-among-omani-adults-with-thalassemia-100641748",false,"NCT07660224","The Effect of Motivational Interviewing on Treatment Adherence and Self-Efficacy Among Omani Adults With Thalassemia","The Effect of Motivational Interviewing on Treatment Adherence and Self-Efficacy Among Omani Adults With Beta-Thalassemia Major","MITAS","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Diagnosed with transfusion-dependent beta-thalassemia major.\n* Receiving iron chelation therapy for at least 6 months.\n* Receiving regular follow-up at the participating study sites.\n* Able to communicate in Arabic or English.\n* Willing and able to provide informed consent.\n* Able to attend the motivational interviewing sessions and complete study questionnaires.\n\nExclusion Criteria:\n\n* Current hospitalization for an acute medical condition at the time of recruitment.\n* Severe cognitive impairment or psychiatric illness that may affect participation.\n* Participation in another structured psychosocial or behavioral intervention program.\n* Unable or unwilling to provide informed consent.","ALL","18 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"NA","Beta-thalassemia major is a chronic hereditary blood disorder that requires lifelong treatment, including regular blood transfusions and iron chelation therapy. Poor adherence to treatment remains a significant challenge and may lead to iron overload and related complications. Self-efficacy is an important factor influencing patients' ability to adhere to treatment recommendations.\n\nThis study aims to evaluate the effect of nurse-delivered Motivational Interviewing (MI) on treatment adherence and self-efficacy among Omani adults with beta-thalassemia major. A pre-experimental one-group repeated-measures design will be used. Approximately 45 participants will be recruited from the Oman National Center for Hematology and Bone Marrow Transplantation and Royal Hospital in Muscat, Oman.\n\nParticipants will receive three individualized MI sessions over a period of six to eight weeks. Treatment adherence and self-efficacy will be assessed at baseline, immediately after completion of the intervention, and at three-month follow-up. Secondary outcomes include serum ferritin level and frequency of thalassemia-related hospital admissions. The findings will provide evidence regarding the usefulness of motivational interviewing in improving adherence-related outcomes among adults with beta-thalassemia major.",[27,28],"Beta-Thalassemia Major","Transfusion-Dependent Thalassemia",[30,27,31,32,33,34,35,36,37],"Motivational Interviewing","Treatment Adherence","Self-Efficacy","Iron Chelation Therapy","Adult Patients","Nursing Intervention","Thalassemia","Oman","NOT_YET_RECRUITING","2026-06-16",{"date":41,"type":42},"2026-06-22","ACTUAL",{"date":44,"type":21},"2026-11-01",{"date":46,"type":21},"2027-11-30",{"name":48,"class":49},"Oman Ministry of Health","OTHER_GOV",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100566608","phase-2-evaluation-of-recombinant-humanized-anti-cd25-monoclonal-antibody-for-preventing-graft-versus-host-disease-after-haploidenticalmatched-unrelated-donor-hematopoietic-stem-cell-transplantation-in-patients-with-transfusion-dependent-thalassemia-100566608","NCT06657391","Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical\u002Fmatched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia","Evaluation of the Clinical Efficacy and Safety of Recombinant Humanized Anti-CD25 Monoclonal Antibody in Preventing Graft-versus-host Disease After Haploidentical \u002F Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia: a Prospective, Multicenter, Open-label, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* patients with transfusion-dependent thalassemia;\n* patients who are planning to receive matched unrelated donor hematopoietic stem cell transplantation (MUD-HSCT) or HLA haploidentical donor hematopoietic stem cell transplantation (HID-HSCT);\n* physical condition score (Lansky\u002FKarnofsky score) ≥ 70%;\n* patients (or legal guardians) voluntarily participate in the study and sign the informed consent form\n\nExclusion Criteria:\n\n* patients with HLA-matched hematopoietic stem cell donors and willing to receive HLA-matched hematopoietic stem cell transplantation;\n* patients with known infectious diseases such as hepatitis B, hepatitis C, AIDS, syphilis, human T-lymphotropic virus, etc.;\n* patients with serious active bacterial, viral, fungal, malaria or parasitic infections;\n* patients with autoimmune deficiency diseases;\n* patients with a history of malignant tumors or current malignant tumors;\n* patients with important organ diseases or abnormal laboratory tests, including but not limited to: 1) patients with cirrhosis, liver fibrosis or active hepatitis, and\u002For abnormal liver function tests (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥2.5×ULN; alkaline phosphatase ≥2.5×ULN); 2) patients with heart disease, or left ventricular ejection fraction (LVEF) \\\u003C60%, or severe iron deposition in the heart; 3) kidney disease, or blood creatinine ≥1.5×ULN with creatinine clearance \\\u003C30% of normal level; 4) patients with endocrine dysfunction;\n* patients with uncorrected bleeding disease;\n* patients with severe mental illness (such as severe depression, schizophrenia, etc.) or cognitive dysfunction (dementia, delirium, etc.), which are unable to cooperate with the study;\n* peripheral blood white blood cell (WBC) count \\\u003C3×10\\^9\u002FL or platelet count \\\u003C100×10\\^9\u002FL;\n* patients having received thalidomide treatment within the past 3 months;\n* patients having received any type of gene and\u002For cell therapy in the past;\n* patients with severe allergies;\n* female patients who are pregnant, breastfeeding, or planning to become pregnant within 1 year of participating in this trial;\n* patients who are participating in other clinical trials;\n* other situations that are not suitable for participation in this clinical trial as assessed by the investigator.","3 Years","20 Years",{"count":60,"type":21},396,[62],"PHASE2","Graft-versus-host disease (GVHD) is a major factor affecting the efficacy and quality of life of alternative donor transplantation in thalassemia major (TM), severely limiting the clinical application of alternative donor transplantation in TM.The purpose of this clinical trial is to evaluate whether recombinant humanized anti-CD25 monoclonal antibody is effective in preventing GVHD and its safety after haploidentical\u002Fmatched unrelated donor hematopoietic stem cell transplantation. The main questions it aims to answer are:\n\n* Does recombinant humanized anti-CD25 monoclonal antibody reduce the incidence of GVHD disease after haploidentical\u002Fmatched unrelated donor hematopoietic stem cell transplantation?\n* What medical problems will participants experience when using the recombinant humanized anti-CD25 monoclonal antibody? What is the quality of life after 2 years follow-up? In this clinical trail, participants will be randomly assigned to the intervention group or the control group by researchers in a 2:1 ratio. The intervention group will be given recombinant humanized anti-CD25 monoclonal antibody (1mg\u002FKg) combined with the standard GVHD prophylaxis after transplantation, while the control group will only receive the standard GVHD prophylaxis. The incidence of GVHD after transplantation in the two groups will be observed. The main evaluation is the clinical efficacy of recombinant humanized anti-CD25 monoclonal antibody in preventing aGVHD.",[65],"Transfusion Dependent Thalassemia","RECRUITING","2024-10-24",{"date":69,"type":42},"2024-10-28",{"date":71,"type":42},"2024-10-01",{"date":73,"type":21},"2027-09-30",{"name":75,"class":76},"Rongrong Liu","OTHER",5,"Transfusion-dependent Thalassemia"]